Based on the survival efficacy from the results of phase II clinical trials, anti-PD1 inhibitors nivolumab and pembrolizumab were approved as the subsequent-line treatment for unresectable HCC (14, 15). Here, PDCD1 is linked to hepatocellular carcinoma.